KELOWNA, BRITISH COLUMBIA--(Marketwire - December 10, 2007) - Sernova Corp. (TSX VENTURE: SVA) (“Sernova”) is pleased to announce completion of a comprehensive preclinical efficacy animal study for its lead product Sertolin, which is a combination of porcine Sertoli cells and pancreatic islet cells for the treatment of diabetes. The benefits of Sertolin are the ability to replace insulin producing cells that have been destroyed in a diabetic patient without the need for anti-rejection drugs, and using the unlimited supply of porcine derived cells. After conferring with its Scientific Advisory Board and regulatory consultants, Sernova believes it has completed the recommended Sertolin preclinical studies and is seeking guidance from health regulators in Canada and the US to determine what, if any, additional data is required prior to applying for approval to begin clinical trials.
